AAV-mediated MUC5AC siRNA delivery to prevent mucociliary dysfunction in asthma.

Area of Science:

• Pulmonary Medicine
• Gene Therapy
• Respiratory Diseases

Background:

• Mucus production in the lungs involves mucin 5B (MUC5B) and mucin 5AC (MUC5AC).
• Asthma is characterized by increased MUC5AC, impairing mucociliary clearance (MCC) and causing mucus plugs.
• MUC5AC is a therapeutic target for asthma treatment.

Purpose of the Study:

• To investigate adeno-associated virus serotype 6 (AAV6) as a gene delivery vector for reducing MUC5AC expression in airway epithelial cells.
• To evaluate AAV6's efficacy in targeting airway epithelial cells and delivering siRNA to suppress MUC5AC.

Main Methods:

• AAV6 vector was used to deliver MUC5AC-targeting siRNA to mouse airways and human airway epithelial (HAE) cells.
• Transduction efficiency and transgene expression were assessed in mouse models.
• Multiple particle tracking analysis evaluated AAV6's ability to penetrate mucus barriers.
• IL-13 stimulated HAE cells were used to model asthma conditions and test AAV6-MUC5AC siRNA treatment.

Main Results:

• AAV6 successfully transduced airway epithelial cells in mice, with high expression in goblet cells.
• AAV6 demonstrated penetration through normal and MUC5AC-enriched mucus.
• AAV6 achieved successful transduction in IL-13 stimulated HAE cells.
• AAV6-MUC5AC siRNA treatment significantly reduced MUC5AC mRNA and protein levels in HAE cells.
• AAV6-MUC5AC siRNA treatment maintained normal mucociliary transport in HAE cells.

Conclusions:

• AAV6 is an effective lung-tropic viral vector for gene delivery to airway epithelial cells.
• Inhaled AAV6 gene therapy can suppress MUC5AC overexpression in asthma models.
• AAV6 holds promise for restoring normal airway clearance function in asthma.